Fairvalue-Calculator Fairvalue-Calculator
EN DE

Guizhou Bailing Group (002424) Fair Value & Analysis

Healthcare · CN · Market cap 6.2B CNY

Price¥4.47
Fair Value¥2.95
Upside-34.0%
Quality95/100
Evidence: High Range ¥2.07 – ¥3.83

Fair value as of: Jun 25, 2026

Analysis

Guizhou Bailing Group (002424) currently trades at ¥4.47, while our model-based Fair Value estimate is ¥2.95 — implying the stock looks roughly 34.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Guizhou Bailing Group Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells medicines in China. It operates through four segments: Industrial, Commerce, Medical institutions, and Others The company offers medicines in various forms, including tablets, capsules, granules, syrups, powders, pills, dews, pastes, sprays, and oral liquids, as well as wines and honey. Its products are used for cardiovascular, cough, cold, gynecological, and pediatric areas. The company was incorporated in 1999 and is headquartered in Anshun, China.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Guizhou Bailing Group (002424) undervalued?
As of Jun 25, 2026, our model estimates a fair value of ¥2.95 versus a price of ¥4.47 — about −34% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 002424?
Our 21-model fair value for Guizhou Bailing Group is ¥2.95 (as of Jun 25, 2026), built from audited fundamentals. The current price is ¥4.47.
What is the quality score of 002424?
Guizhou Bailing Group has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.